Current Research Studies

Capricor Hope-3 study

Condition(s): Other
Phase: III

What is the goal of the study?

The purpose of the clinical trial is to assess the efficacy and safety of the investigational product (IP), CAP-1002, administered every 3 months by IV infusion in subjects with Duchenne muscular dystrophy and impaired skeletal muscle function.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Seth Perlman
Study Team Member: Richard Torres, richard.torres@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.